Shares of PhioPharmaceuticalsCorp . stock traded up $0.02 during trading on Monday, hitting $0.50. 239,691 shares of the company’s stock were exchanged, compared to its average volume of 619,545. PhioPharmaceuticalsCorp . has a 52-week low of $0.27 and a 52-week high of $2.84. The stock has a market cap of $11.04 million, a PE ratio of -0.48 and a beta of 2.05.
PhioPharmaceuticalsCorp . (NASDAQ:PHIO) last issued its earnings results on Wednesday, March 27th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. PhioPharmaceuticalsCorp . had a negative net margin of 4,990.20% and a negative return on equity of 153.67%. On average, analysts predict that PhioPharmaceuticalsCorp . will post -0.37 earnings per share for the current fiscal year.
PhioPharmaceuticalsCorp . Company Profile
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.
Further Reading: What Is An Exchange-Traded Fund (ETF)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for PhioPharmaceuticalsCorp . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhioPharmaceuticalsCorp . and related companies with MarketBeat.com's FREE daily email newsletter.